Yiru Shi

Dr Yiru Shi

Grant-Funded Researcher (A)

SAIGENCI

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr. Yiru Shi obtained her Master of Science in Biotechnology from the University of Queensland in 2019 and earned her PhD in 2025 from Australian Institute of Bioengineering (AIBN), University of Queensland. She is currently a postdoctoral researcher at the South Australian immunoGENomics Cancer Institute (SAiGENCI), the University of Adelaide. Shi is committed to developing innovative in situ vaccine strategies for cancer immunotherapy.During her PhD, Yiru focused on engineering smart nano- and biomaterials to stimulate robust antitumor immune responses within the tumor microenvironment. Her research emphasized the design of nanoparticles combined with oncolytic peptides to promote immunogenic cell death and enhance immune activation. This work led to the development of a multifunctional in situ cancer vaccine platform that demonstrated potent systemic antitumor immunity in preclinical models.Dr. Shi joined SAiGENCI to continue her work on next-generation in situ vaccines for cancer immunotherapy. Her interdisciplinary approach integrates rational biomaterial design with immune engineering to address critical challenges in the treatment of solid tumors.

Date Position Institution name
2025 - ongoing Postdoctoral Researcher University of Adelaide

Date Institution name Country Title
2021 - 2025 University of Queensland Australia PhD
2018 - 2019 University of Queensland Australia MSc

Year Citation
2026 Dai, Z., Wang, Q., Zhang, M., Shi, Y., Yang, Y., Song, H., . . . Yu, C. (2026). Tumor-activated nanocomplex reprograms cancer and macrophage metabolism in opposite directions to overcome immune suppression. Biomaterials, 326, 123655.
DOI
2025 Luo, J., Wang, Y., Dai, Z., Shi, Y., Wu, W., Qu, J., . . . Yang, Y. (2025). Passivation-Engineered Zinc Peroxide Nanoparticles as Th1-Biased Adjuvant for Antitumor Immunity. Small, 21(42), e05250-1-e05250-14.
DOI
2025 Xian, H., Song, Y., Qu, J., Shi, Y., Zhang, Y., Wu, W., . . . Yu, C. (2025). CaClOH-Modified Silica Nanoparticles for mRNA Delivery. Nano Letters, 25(16), 6365-6373.
DOI Scopus3 WoS3 Europe PMC1
2025 Shi, Y., Hou, Y., Mabrouk, M. T., Yu, C., & Yang, Y. (2025). In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation. Advanced Science, 12(37), 23 pages.
DOI Scopus3 WoS3 Europe PMC1
2024 Yang, Y., Chen, S., Zhang, M., Shi, Y., Luo, J., Huang, Y., . . . Yu, C. (2024). Mesoporous nanoperforators as membranolytic agents via nano- and molecular-scale multi-patterning.. Nat Commun, 15(1), 1891.
DOI Scopus4 WoS4 Europe PMC3
2023 Shi, Y., Dai, Z., Wang, Y., Luo, J., Cai, L., Tang, J., . . . Yang, Y. (2023). Engineering Crystallinity Gradients for Tailored CaO₂ Nanostructures: Enabling Alkalinity-Reinforced Anticancer Activity with Minimized Ca²⁺/H₂O₂ Production. Nano letters, 23(23), 10657-10666.
DOI Scopus6 WoS6 Europe PMC2
2020 Wang, Y., Yang, Y., Shi, Y., Song, H., & Yu, C. (2020). Antibiotic-Free Antibacterial Strategies Enabled by Nanomaterials: Progress and Perspectives. Advanced Materials, 32(18), 1-21.
DOI Scopus730 WoS716 Europe PMC319
2020 Shi, Y., Fu, J., & Yang, Y. (2020). Effects of synthetic routes on the compositional and structural properties of dendritic mesoporous organosilica nanoparticles: The unexpected reversed “double-edged sword” role of reaction time. Microporous and Mesoporous Materials, 294, 1-8.
DOI Scopus6 WoS5

Year Citation
- Shi, Y. (n.d.). Development of calcium-based nanoparticles for in situ vaccines.

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor Bioengineered Therapeutic Platforms for Cancer Immunotherapy Doctor of Philosophy Doctorate Full Time Miss Yuxuan Hou
2025 Co-Supervisor Bioengineered Therapeutic Platforms for Cancer Immunotherapy Doctor of Philosophy Doctorate Full Time Miss Yuxuan Hou

Connect With Me

External Profiles

Other Links